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Abstract
Introduction and hypothesis As in the case of cardiovascular
and metabolic diseases, the prevalence of pelvic organ pro-
lapse (POP) has been rising with the increasing proportion of
elderly women in the population. The purpose of the present
cross-sectional study was to evaluate the components of met-
abolic syndrome (MS) in urogynecological patients with a
variable POP severity.
Methods The MS risk factors (elevated waist circumference,
elevated triglycerides, decreased high-density lipoprotein cho-
lesterol, elevated blood pressure, hyperglycemia) were
assessed in 100 women who were referred to our
urogynecological center with pelvic floor disorders (PFD).
POP was evaluated with the Pelvic Organ Prolapse
Quantification system (POP-Q).
Results The χ2 test revealed that the diagnosis of MS and the
presence of elevated triglycerides increased with the overall
POP-Q stage. The other MS risk factors were not significantly
associated with the overall POP-Q stage. MS and elevated
triglycerides were predictors of the POP-Q stage ≥III [odds
ratio (OR) 3.5, 95 % confidence interval (CI) 1.5–8.2 for MS
and OR 3.4, 95 % CI 1.4–8.2 for elevated triglycerides,
p<0.01].
Conclusions The diagnosis of MS and the presence of elevat-
ed triglycerides may be associated with the severity of POP in
urogynecological patients. Longitudinal studies are required
to assess whether the MS risk factors might predict the pro-
gression of POP and whether elimination of the risk factors
might improve the prognosis in POP patients.
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Abbreviations
BMI Body mass index
CI Confidence interval
CRADI-8 Colorectal-Anal Distress Inventory 8




PFD Pelvic floor disorders
PFDI-20 Pelvic Floor Distress Inventory 20
POP Pelvic organ prolapse
POPDI-6 Pelvic Organ Prolapse Distress Inventory 6
POP-Q Pelvic Organ Prolapse Quantification
SUI Stress urinary incontinence
tvl Total vaginal length
UDI-6 Urinary Distress Inventory 6
Introduction
Pelvic organ prolapse (POP) imposes a significant medical,
psychological, and economic burden on individual patients
and societies [1–3]. The prevalence of POP has been rising
with the increasing proportion of elderly women in the
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population. It has been reported that about 50 % of parous
women develop POP symptoms [4] and the lifetime risk of
POP surgery is 11 % [5]. The cause of POP is considered to be
multifactorial [3, 6]. Vaginal childbirth, ageing, increased
body mass index (BMI), levator ani avulsions, and variations
in shape of the bony pelvis may all constitute risk factors for
POP [1, 3, 7].
Some of the above risk factors increase the risk of devel-
oping POP but not its severity once patients become symp-
tomatic. For example, although obesity increases the risk of
developing vaginal prolapse [1], BMI is not correlated with
POP severity assessed with the Pelvic Organ Prolapse
Quantification system (POP-Q) [8, 9]. Washington et al. [10]
reported no significant difference in stage ≥II prolapse be-
tween obese and nonobese patients seeking care for pelvic
floor disorders (PFD). In line with the above, no correlation
was observed between BMI and the overall POP-Q stage in a
retrospective study on women with symptomatic prolapse
presenting to an outpatient urogynecological center [9].
Most studies showing a positive correlation between obe-
sity and POP focused on the theory of increased abdominal
pressure. According to the theory, chronic obesity-related
increase in abdominal pressure stresses the pelvic floor and
leads to structural damage and/or neurological dysfunction
predisposing to POP [1, 6]. Obesity-related metabolic and
vascular complications [11, 12] have received relatively little
attention in the discussion on the pathophysiology of POP.
Decades of research have revealed abdominal obesity to be a
precursor and crucial aspect of metabolic syndrome (MS), a
cluster of interrelated risk factors for cardiovascular disorders,
which occur together more often than by chance alone
[13–15]. The recently updated criteria for clinical diagnosis
of MS include elevated waist circumference, elevated triglyc-
erides, reduced high-density lipoprotein cholesterol, elevated
blood pressure, and hyperglycemia [13].
A possible relationship between MS and POP has not been
addressed in much detail. In their single cross-sectional study,
Kim et al. [16] analyzed correlations between MS and the
severity of POP symptoms assessed with the Pelvic Floor
Distress Inventory 20 (PFDI-20) in Korean women recruited
during a routine medical screening. The PFDI-20 is a
condition-specific questionnaire consisting of 20 questions
divided into 3 subscales: the Pelvic Organ Prolapse Distress
Inventory 6 (POPDI-6), Colorectal-Anal Distress Inventory 8
(CRADI-8), and Urinary Distress Inventory 6 (UDI-6) [17]. In
the study by Kim et al. [16], the presence of MS was associ-
ated with the total PFDI-20 score and the CRADI-8, UDI-6,
and POPDI-6 subscores. Among the MS criteria, only elevat-
ed waist circumference and elevated triglycerides were signif-
icant risk factors for POP symptoms. It should be remembered
that the assessment of POP symptoms in the latter study was
based on the patient’s self-report, performed in a primary care
setting, and limited to Asian women [16]. It remains to be
established whether a similar relationship exists between MS
and the severity of POP diagnosed on the basis of physical
examination and the POP-Q staging in urogynecological pa-
tients of Caucasian origin.
The purpose of the present pilot, cross-sectional study was
to evaluate the MS risk factors in urogynecological patients
with different POP severity. Given the data reported by Kim
et al. [16], we hypothesized that patients with a greater overall
POP-Q stage are more likely to be diagnosedwithMS and that




The study was carried out in accordance with the Declaration
of Helsinki of the World Medical Association. The study
protocol was approved by the Ethics Committee for Human
Studies of the Military Institute of Medicine, Warsaw, Poland.
All participants signed an informed consent form after study
procedures had been fully explained.
Women (n=490) who were referred to the Outpatient
Clinic of the Department of Gynecology in 2012 with PFD
as a chief complaint were screened for eligibility [9, 10; for
details, see Fig. 1]. A total of 108 patients diagnosed with POP
with the POP-Q staging system were considered potential
participants. Exclusion criteria comprised a prior bariatric or
PFD surgery and having a serious medical condition which
might render the interpretation of results difficult (e.g., hepatic
or renal insufficiency, cancer treatment, a genetic connective
tissue disease, alcohol dependence).We also excluded women
who had received current or recent hormone replacement
therapy (HRT) to avoid the likely association between HRT
and lipid profiles [18].
Study methods and definitions conformed to the standards
jointly recommended by the International Urogynecological
Association and the International Continence Society
(IUGA/ICS) [19]. The pelvic examination was performed
with the patient in the dorsal lithotomy position. The POP-Q
system was used to quantify the severity of POP at a maxi-
mum Valsalva strain [8]. Stage 0 implies normal anatomy,
without prolapse in the vaginal compartment. In patients with
stage I prolapse, the leading edge of the prolapse was >1 cm
above the level of the hymen. For stage II, the most distal
portion of the prolapse was within 1 cm of the hymen. In
patients with stages III and IV, the leading edge of the prolapse
protruded the hymen. In those at stage IV, the prolapse pro-
truded the greatest distance [total vaginal length (tvl) − 2] cm
beyond the plane of the hymen [8, 9, 20]. The patients were
screened for stress urinary incontinence (SUI) symptoms
using the Stamey Incontinence Score [21]. Those scoring ≥1
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were considered to be SUI positive [20]. Overactive bladder
(OAB) symptoms were assessed by using questions selected
from the PFDI [22] as described by Rogowski et al. [20].
The final study group included 100 Caucasian women with
overall POP-Q stage I–IV (stage I, n=22, stage II, n=21, stage
III, n=46, stage IV, n=11). These patients were screened for
the presence of MS risk factors as reported by other authors
[11, 14, 16]. For each patient, the MS criteria were assessed in
the Outpatient Clinic of the Department of Gynecology.
Anthropometric measurements (weight, height) were made
with the patients wearing light clothes with no shoes. BMI
was calculated as weight (in kg) divided by height (in square
meters). Waist circumference was measured on minimal in-
spiration with a tape with 0.5-cm accuracy from the narrowest
point between the lower rib border and the iliac crest. Blood
pressure was taken at least twice, with the patient in a sitting
position, after a 10-min period of relaxation. Blood samples
were collected in the morning after a 12-h fast and sent to the
laboratory of the Military Institute of Medicine. Commercial
enzymatic tests were used to determine fasting glucose, tri-
glycerides, and high-density lipoprotein cholesterol [11, 14,
16].
The patients were diagnosed withMS if any three (or more)
of the following five risk factors were present: (1) abdominal
obesity, i.e., waist circumference ≥80 cm, (2) hyperglycemia,
i.e., fasting glucose ≥100 mg/dl (or treatment for elevated
glucose), (3) hypertriglyceridemia, i.e., fasting triglycerides
≥150 mg/dl (or treatment for elevated triglycerides),(4) high-
density lipoprotein cholesterol <50 mg/dl (or treatment for
reduced high-density lipoprotein cholesterol), and (5) elevated
blood pressure, i.e., systolic pressure ≥130 mmHg and/or
diastolic pressure ≥85 mmHg (or antihypertensive drug treat-
ment in patients with a history of hypertension) [13, 14].
Statistics
Sociodemographic and clinical parameters were expressed as
means (±SD) or proportions (n/N). The subgroups of patients
with a different POP-Q stage were compared with the one-
way analysis of variance (ANOVA) or the χ2 test. Odds ratios
(ORs) with 95 % confidence intervals (CI) were used to
estimate the strength of associations between the MS risk
factors and the POP-Q stage. The number of subjects with
POP-Q stage IV was relatively small, and thus for some
statistical analyses the patients were pooled into two groups
(POP-Q stage I–II and POP-Q stage III–IV). ORs with 95 %
CI were calculated for the association between the MS risk
factors and the POP-Q stage ≥III.
A probability level (p) less than 0.05 was considered sig-
nificant. All statistical analyses were performed using the
Statistica 5.0 software package (StatSoft, Tulsa, OK, USA).
Results
Figure 1 shows the detailed flow chart of patients’ recruit-
ment. Table 1 shows basic sociodemographic and clinical
characteristics of the study participants with different POP-Q
stages (I–IV). The four groups did not differ in age, BMI,
smoking status, gravidity, parity, and OAB symptoms.
Similarly, there were no differences in the above parameters
when the patients with POP-Q stage ≤II (stage I–II) were
compared with those with stage ≥III (stage III–IV; all p>0.05).
The χ2 test showed a significant difference between the
four groups in the proportion of postmenopausal women. The
above difference was mainly due to the fact that more pre-
menopausal patients were classified as stage I. Theχ2 test also
revealed significant differences between the four groups in the
proportion of women reporting SUI symptoms. The propor-
tion of SUI-positive patients tended to decrease with increas-
ing POP-Q stage (Table 1).
n=490 ambulatory 
patients with PFD as a 
chief complaint
n=68 patients after 
PFD surgery
n=314 patients with 
SUI and/or OAB and 
without POP
n=108 POP patients
with no history of PFD 
surgery
n=3 patients 
who did not agree 
to participate
n=1 patient





finally recruited to 
the study
Fig. 1 Flow chart of patients’ recruitment
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The prevalence of MS and its components in the groups
with different POP-Q stages is shown in Table 2. The χ2 test
indicated that the prevalence of elevated waist circumference,
reduced high-density lipoprotein cholesterol, elevated blood
pressure, and elevated fasting glucose did not differ between
the four groups. The proportion of patients with elevated
triglycerides increased with increasing POP-Q stage.
Similarly, the proportion of women meeting the criteria for
MS increased with increasing POP-Q stage (Table 2). The
calculation of ORs with 95 % CI confirmed that elevated
triglycerides and the diagnosis of MS were significant predic-
tors of POP-Q stage ≥III (Table 3).
Since the four groups (POP-Q stage I–IV) differed in the
number of postmenopausal women, a separate analysis was
performed to study the association between MS and POP-Q
stage after the exclusion of 13 premenopausal patients. The
numbers of stage I and stage IV patients were relatively low,
and thus the remaining postmenopausal subjects were pooled
into two groups (postmenopausal/POP-Q stage I–II vs
postmenopausal/POP-Q stage III–IV). The proportion of wom-
en with MS was significantly higher in the postmenopausal/
stage III–IV group (31/55) as compared to the postmenopausal/
stage I–II group [11/32;χ2 (1)=3.9, p<0.05]. The proportion of
womenwith elevated triglycerides was also significantly higher
in the postmenopausal/stage III–IV group (29/55) in compari-
son with the postmenopausal/stage I–II group [7/32; χ2 (1)=
7.9, p<0.01]. The postmenopausal/stage III–IV and
postmenopausal/stage I–II subjects did not differ in the preva-
lence of the other MS components (p>0.05).
Discussion
To the best of our knowledge, this is the first study showing
that MS and some of its components may be associated with
the severity of POP assessed with the POP-Q staging system
in urogynecological patients seeking help for PFD. The prev-
alence of MS in the POP-Q stage III–IV group was twice as
high as the prevalence found in the POP-Q stage I–II group.
Notably, the prevalence of MS observed in the whole study
group (42 %) was similar to that reported recently for a
representative sample of Polish women recruited in the com-
munity (from 39 to 44 % depending on the MS definition)
[23].
Table 1 Sociodemographic and clinical characteristics of patients (n=100) with different POP-Q stages
Parameter Stage I Stage II Stage III Stage IV Statistics
Age (years)a 60.1±14.2 60.3±9.0 64.7±7.9 63.1±8.9 F(3,96)=1.5, p=0.2
BMI (kg/m2)a 27.1±3.9 28.9±5.3 28.5±5.1 26.4±4.8 F(3,96)=1.0, p=0.4
Current smokersb 1/22 3/21 2/46 1/11 χ2 (3)=2.5, p=0.4
Graviditya 2.2±1.2 2.5±1.0 2.5±1.5 2.9±1.8 F(3,96)=0.6, p=0.6
Paritya 1.9±0.9 2.2±1.0 1.9±1.2 2.3±1.3 F(3,96)=0.6, p=0.6
Postmenopausal statusb 13/22 19/21 44/46 11/11 χ2 (3)=20.0, p=0.0001
SUI symptomsb 19/22 14/21 17/46 5/11 χ2 (3)=16.4, p=0.0009
OAB symptomsb 8/22 9/21 16/46 3/11 χ2 (3)=0.8, p=0.9
POP-Q Pelvic Organ Prolapse Quantification system [8]
aMean±SD
b n/N
Table 2 MS and its components in patients with different POP-Q stages
Risk factor Stage I Stage II Stage III Stage IV Statistics
Elevated waist circumference 15/22 19/21 39/46 8/11 χ2 (3)=4.5, p=0.2
Elevated triglycerides 6/22 4/21 24/46 5/11 χ2 (3)=8.3, p=0.04
Reduced high-density lipoprotein cholesterol 1/22 4/21 10/46 1/11 χ2 (3)=3.8, p=0.3
Elevated blood pressure 14/22 17/21 28/46 5/11 χ2 (3)=4.4, p=0.2
Elevated fasting glucose 4/22 6/21 19/46 4/11 χ2 (3)=3.9, p=0.3
MSa 3/22 8/21 26/46 5/11 χ2 (3)=11.4, p=0.009
Data presented as n/N
POP-Q Pelvic Organ Prolapse Quantification system [8]
a The presence of any 3 (or more) of 5 risk factors constituted a diagnosis of MS [13]
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The associations between MS, triglycerides, and POP-Q
stage remained significant regardless of whether the whole
group or the postmenopausal women were included in the
statistical analyses. Interestingly, only the diagnosis of MS
and the presence of elevated triglycerides, but not the other
MS components, were significantly associated with POP-Q
stage. In line with previous reports [9, 10], neither BMI nor
waist circumference was correlated with POP-Q stage in the
present study. Thus, increased BMI and obesity may be risk
factors for POP but not necessarily for POP severity once
patients become symptomatic [9, 10].
A relationship between MS risk factors and POP has not
been addressed in much detail in the gynecological literature.
Our findings closely correspond with the results of the report
by Kim et al. [16] showing that the presence of MS was
associated with the severity of POP symptoms assessed with
the POPDI-6. Among the MS criteria, only elevated waist
circumference and elevated triglycerides were related to POP
symptoms. The assessment of POP symptoms in the latter
study was based on the patient’s self-report, performed in a
primary care setting, and limited to Asian women [16]. Hence,
it seems that the association between MS, elevated triglycer-
ides, and the severity of POP is not specific to a particular
technique of assessment (the questionnaire in primary care vs
physical examination in urogynecological patients) or the
patient’s ethnicity (Asian vs Caucasian).
MSmay increase the severity of POP through different, but
not mutually exclusive, mechanisms. It has been repeatedly
reported that patients with MS show microvascular patholog-
ical conditions secondary to endothelial dysfunction and ath-
erosclerosis. MS also increases the risk of prothrombotic and
proinflammatory states [12, 14, 15, 24]. The above patholog-
ical conditions may be associated with remodeling of pelvic
floor connective tissues leading to aberrations in synthesis
and/or degradation of collagen and elastin fibers [6, 25].
The present results suggest that triglycerides are specifical-
ly involved in POP pathology. The prevalence of elevated
triglycerides in our patients (stage ≤II 23.2 %, stage ≥III
50.9 %) was clearly higher than the prevalence found
(12.5 %) in a representative sample of Polish women (age
56.4±11.8 years, BMI 27.9±5.1 kg/m2) recruited in the com-
munity [23]. The role of triglycerides in POP has not been
addressed in systematic preclinical or clinical studies.
Hypertriglyceridemia is a common lipid metabolic dis-
order, often of genetic origin, which may be modeled in
laboratory animals [26, 27]. If triglycerides play a spe-
cific role in POP, more POP symptomatology may be
expected in women with primary hypertriglyceridemia
[27] and in animal models of hypertriglyceridemia [26,
28]. The above hypotheses can be addressed in further
experimental and clinical studies.
In the present study, the self-reported SUI symptoms were
negatively correlated with the presence of MS. Interestingly,
Kim et al. [16] showed a positive correlation between MS and
variousmicturition disorders evaluatedwith theUDI-6 inAsian
women. One should be aware that the real prevalence of SUI in
patients with POP-Q stage ≥III is probably higher than
might be inferred from the self-report. It has been shown
that POP may obstruct the urethra and advanced POP is
often associated with occult urinary incontinence [29].
Further studies should be conducted to evaluate possible
associations between MS and urinary incontinence in
patients with and without POP.
The present study involves some limitations.We included a
relatively small sample of patients recruited in one
urogynecological center localized in an urban area. The study
was cross-sectional in nature and does not enable a judgment
about casual relationships or validity of theMS risk factors for
predicting the progression of POP. One should also remember
that MS and elevated triglycerides may not be independent
predictors of POP. Further studies on larger samples are need-
ed to replicate the present findings and to evaluate whether
MS and elevated triglycerides are independent risk factors for
POP severity.
Given the significance of POP for individual patients and
societies [1, 2], longitudinal studies are needed to evaluate
whether the presence of MS alters the prognosis in POP
patients. If yes, it would be of critical importance to evaluate
whether patients’ counseling and/or pharmacotherapy aimed
at eliminating theMS risk factors could inhibit the progression
of POP.
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Table 3 MS and its components as predictors of increased POP-Q stage
Risk factor OR 95 % CI p value
Elevated waist circumference 1.2 0.4–3.5 p=0.7
Elevated triglycerides 3.4 1.4–8.2 p=0.006
Reduced high-density lipoprotein cholesterol 1.8 0.6–5.7 p=0.3
Elevated blood pressure 0.5 0.2–1.2 p=0.1
Elevated fasting glucose 2.2 0.9–5.4 p=0.1
MS 3.5 1.5–8.2 p=0.005
43 patients were classified as POP-Q stage ≤II and 57 patients were
classified as POP-Q stage ≥III; univariate regression analysis was used
to predict stage ≥III
POP-Q Pelvic Organ Prolapse Quantification system [8]
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